CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss		$ (35,806)	$ (25,770)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense		5,049	5,340
Depreciation and amortization		5,118	5,640
Noncash operating lease cost		799	686
Amortization of discount on short-term investments		(2,204)	(1,264)
Other		(263)	8
Changes in operating assets and liabilities
Accounts receivable	[1]	(1,812)	4,809
Inventory and other deferred costs		504	1,271
Prepaid expenses and other assets		(1,133)	879
Accounts payable	[2]	3,721	(5,101)
Accrued and other current liabilities	[2]	(1,294)	(5,513)
Contract liabilities		(1,475)	(2,701)
Operating lease liabilities		(2,000)	(1,701)
Other long-term liabilities	[2]	(100)
Net cash used in operating activities		(30,896)	(31,156)
Cash flows from investing activities:
Purchases of available-for-sale debt securities		(108,297)	(37,836)
Proceeds from maturities of available-for-sale debt securities		84,185	57,000
Purchases of property and equipment		(2,801)	(110)
Proceeds from sales of property and equipment			240
Net cash (used in) provided by investing activities		(26,913)	19,294
Cash flows from financing activities:
Proceeds from sales of common stock under ATM facility, net of commissions		17,782	2,842
Payment of costs related to Tempus and Merck Investment Agreements		(106)
Proceeds from loans		2,587
Repayments of loans		(1,307)	(514)
Proceeds from issuance of common stock under equity incentive plans		804	317
Net cash provided by financing activities		19,760	2,645
Effect of exchange rates on cash, cash equivalents and restricted cash		8	(20)
Net change in cash, cash equivalents and restricted cash		(38,041)	(9,237)
Cash, cash equivalents and restricted cash, beginning of period		93,205	58,774
Cash, cash equivalents and restricted cash, end of period		55,164	49,537
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents		53,374	47,747
Restricted cash, included in other long-term assets		1,790	1,790
Total cash, cash equivalents and restricted cash		$ 55,164	49,537
Tempus Warrants
Adjustments to reconcile net loss to net cash used in operating activities
Noncash gain related to liability classified Tempus Warrants			$ (7,739)

[1] (1) Includes a change in related party receivable of $0.6 million for the six months ended June 30, 2025.

[2] (2) Includes a change in related party liabilities of $1.9 million for the six months ended June 30, 2025.